Cargando…

Immunotherapy for Alzheimer’s disease: past, present and future

Alzheimer’s disease (AD) is an incurable, progressive, neurodegenerative disorder affecting over 5 million people in the US alone. This neurological disorder is characterized by widespread neurodegeneration throughout the association cortex and limbic system caused by deposition of Aβ resulting in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Spencer, Brian, Masliah, Eliezer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4051211/
https://www.ncbi.nlm.nih.gov/pubmed/24959143
http://dx.doi.org/10.3389/fnagi.2014.00114
_version_ 1782320077461258240
author Spencer, Brian
Masliah, Eliezer
author_facet Spencer, Brian
Masliah, Eliezer
author_sort Spencer, Brian
collection PubMed
description Alzheimer’s disease (AD) is an incurable, progressive, neurodegenerative disorder affecting over 5 million people in the US alone. This neurological disorder is characterized by widespread neurodegeneration throughout the association cortex and limbic system caused by deposition of Aβ resulting in the formation of plaques and tau resulting in the formation of neurofibrillary tangles. Active immunization for Aβ showed promise in animal models of AD; however, the models were unable to predict the off-target immune effects in human patients. A few patients in the initial trial suffered cerebral meningoencephalitis. Recently, passive immunization has shown promise in the lab with less chance of off-target immune effects. Several trials have attempted using passive immunization for Aβ, but again, positive end points have been elusive. The next generation of immunotherapy for AD may involve the marriage of anti-Aβ antibodies with technology aimed at improving transport across the blood-brain barrier (BBB). Receptor mediated transport of antibodies may increase CNS exposure and improve the therapeutic index in the clinic.
format Online
Article
Text
id pubmed-4051211
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-40512112014-06-23 Immunotherapy for Alzheimer’s disease: past, present and future Spencer, Brian Masliah, Eliezer Front Aging Neurosci Neuroscience Alzheimer’s disease (AD) is an incurable, progressive, neurodegenerative disorder affecting over 5 million people in the US alone. This neurological disorder is characterized by widespread neurodegeneration throughout the association cortex and limbic system caused by deposition of Aβ resulting in the formation of plaques and tau resulting in the formation of neurofibrillary tangles. Active immunization for Aβ showed promise in animal models of AD; however, the models were unable to predict the off-target immune effects in human patients. A few patients in the initial trial suffered cerebral meningoencephalitis. Recently, passive immunization has shown promise in the lab with less chance of off-target immune effects. Several trials have attempted using passive immunization for Aβ, but again, positive end points have been elusive. The next generation of immunotherapy for AD may involve the marriage of anti-Aβ antibodies with technology aimed at improving transport across the blood-brain barrier (BBB). Receptor mediated transport of antibodies may increase CNS exposure and improve the therapeutic index in the clinic. Frontiers Media S.A. 2014-06-10 /pmc/articles/PMC4051211/ /pubmed/24959143 http://dx.doi.org/10.3389/fnagi.2014.00114 Text en Copyright © 2014 Spencer and Masliah. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Spencer, Brian
Masliah, Eliezer
Immunotherapy for Alzheimer’s disease: past, present and future
title Immunotherapy for Alzheimer’s disease: past, present and future
title_full Immunotherapy for Alzheimer’s disease: past, present and future
title_fullStr Immunotherapy for Alzheimer’s disease: past, present and future
title_full_unstemmed Immunotherapy for Alzheimer’s disease: past, present and future
title_short Immunotherapy for Alzheimer’s disease: past, present and future
title_sort immunotherapy for alzheimer’s disease: past, present and future
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4051211/
https://www.ncbi.nlm.nih.gov/pubmed/24959143
http://dx.doi.org/10.3389/fnagi.2014.00114
work_keys_str_mv AT spencerbrian immunotherapyforalzheimersdiseasepastpresentandfuture
AT masliaheliezer immunotherapyforalzheimersdiseasepastpresentandfuture